Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
Rigel (Nasdaq: RIGL) will report third quarter 2025 financial results after market close on Tuesday, November 4, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rigel (Nasdaq: RIGL) will report third quarter 2025 financial results after market close on Tuesday, November 4, 2025. Senior management will host a live conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and provide a business update. Participants can join via domestic dial-in 877-407-3088 or international 201-389-0927, and the webcast (with slides) will be available on the company Investor Relations website at www.rigel.com.
The webcast will be archived for 90 days after the call. Rigel is a biotechnology company focused on therapies for hematologic disorders and cancer, headquartered in South San Francisco.
Details
News Market Reaction – RIGL
On Oct 29, the day this news came out, RIGL closed 0.98% below the previous close.
Data tracked by StockTitan Argus for the Oct 29 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 646.461.6387
Email: david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2025-financial-results-and-business-update-302597734.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.